MS drug prevented fatal heart condition in lab study

A drug used to treat multiple sclerosis may also be effective at preventing and reversing the leading cause of heart attack, a new study has found.

Scientists found that Gilenya, a drug recently approved in the US for treating MS, was effective at reversing the symptoms of ventricular hypertrophy in mice.

Ventricular hypertrophy is a fatal cardiac disorder that can result in an (arrhythmia) and cardiac arrest. It is caused by sustained pressure on the due to stresses or diseases, such as hypertension (), valvular heart disease or (heart attack), and is the leading cause of worldwide.

Researchers from The University of Manchester and the University of Illinois at Chicago have discovered that enhancing the activity of an enzyme molecule called Pak1 that is found naturally in our bodies using Gilenya produced remarkable results in mice with ventricular hypertrophy.

Study co-author Dr Xin Wang, a Lecturer in Molecular Cardiology in Manchester's Faculty of Life Sciences, said: " is the pathological state to respond to sustained stresses on the heart resulting in increases in ventricular wall thickness and muscle mass of the heart. The condition is often associated with fatal complications, such as, and rhythm disorders, such as ventricular arrhythmias, leading to millions of deaths worldwide each year.

"Our research had previously identified the effect of Pak1 in preventing tissue damage caused by reduced blood flow to the heart, known as cardiac ischemic injury. This latest study used mice with a genetic modification of the Pak1 gene to show how the enzyme, when stimulated by Gilenya, prevented and even reversed the symptoms of ventricular hypertrophy."

The research, led in Manchester by Dr Ming Lei, Dr Xin Wang and Dr Elizabeth Cartwright, and in Chicago by Professor John Solaro and Dr Yunbo Ke, is published in the leading cardiovascular journal, Circulation.

Dr Lei, who is based in Manchester's Faculty of Medical and Human Sciences, added: "In recent years, escalating costs, risks, and uncertainty associated with drug development for treating cardiovascular diseases have posed daunting challenges to the pharmaceutical industry. Our discovery opens up fresh avenues for developing a new class of drug for treating several fatal heart conditions. The novel effect of this existing drug means that we have the potential to accelerate the availability of a new therapy for patients with these heart conditions."

More information: 'Pak1 as a Novel Therapeutic Target for Antihypertrophic Treatment in the Heart,' published in Circulation, doi:10.1161/CIRCULATIONAHA.111.048785

Related Stories

Recommended for you

Most seniors eligible for statin Rx under new guidelines

6 hours ago

(HealthDay)—Most older Americans qualify for treatment with statins under new guidelines for the treatment of blood cholesterol released late last year by the American College of Cardiology and the American ...

Asymptomatic atherosclerosis linked to cognitive impairment

20 hours ago

In a study of nearly 2,000 adults, researchers found that a buildup of plaque in the body's major arteries was associated with mild cognitive impairment. Results of the study conducted at the University of Texas (UT) Southwestern ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.